Taro Resolves U.S. Investigations on Generic Drugs

Taro Pharmaceutical Industries said its wholly owned subsidiary, Taro Pharmaceuticals USA, has resolved all cases involving the company in connection with the multiyear investigations by the Department of Justice, Antitrust Division and Civil Division into the U.S. generic pharmaceutical industry.

• In a separate release, the DoJ said Taro has been charged for conspiring to fix prices, allocate customers, and rig bids for generic drugs,
• Under a deferred prosecution agreement reached with the DOJ, the DOJ will file an Information for conduct that took place between 2013 and 2015. If the company adheres to the terms of the agreement, including the ...